Related Experiment Video

Updated: May 15, 2026

Tissue Collection and RNA Extraction from the Human Osteoarthritic Knee Joint
06:06

Tissue Collection and RNA Extraction from the Human Osteoarthritic Knee Joint

Published on: July 22, 2021

Juvenile idiopathic arthritis: an update for the clinician

Philip Kahn1

  • 1New York University School of Medicine, Division of Pediatric Rheumatology, New York, NY 10016, USA. philip.kahn@nyumc.org

Bulletin of the NYU Hospital for Joint Diseases
|December 25, 2012
PubMed

Insights

Juvenile idiopathic arthritis (JIA) is a chronic childhood arthritis causing pain and deformity. Newer biologic therapies offer targeted treatment, improving outcomes and research towards a potential cure.

Area of Science:

  • Pediatric Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Juvenile idiopathic arthritis (JIA) is a prevalent chronic childhood arthritis with unknown etiology.
  • It can lead to severe joint damage, growth issues, and persistent adult arthritis.
  • Historically, treatments were non-specific with considerable side effects.

Purpose of the Study:

  • To review the clinical characteristics of JIA.
  • To provide current and emerging pharmacotherapy updates for JIA management.

Main Methods:

  • Literature review of clinical features and pharmacotherapy for JIA.
  • Analysis of advancements in targeted biologic therapies.
  • Discussion of ongoing translational research and clinical trials.

Main Results:

  • JIA presents with chronic joint inflammation in children, potentially leading to long-term complications.
  • Biologic agents represent a significant advancement, offering targeted and better-tolerated treatment options.
  • Ongoing research aims to elucidate disease mechanisms for improved therapies and potential cures.

Conclusions:

  • JIA requires comprehensive management strategies.
  • Biologics have transformed JIA treatment, enhancing efficacy and tolerability.
  • Future research holds promise for more effective treatments and a cure for JIA.

Related Concept Videos

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Chronic Inflammation: Introduction01:12

Chronic Inflammation: Introduction

Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Inflammatory Bowel Disease I: Introduction01:26

Inflammatory Bowel Disease I: Introduction

Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...